ADORA2A and bladder transitional cell carcinoma: For example, LINC00607, PART1, AC025165.8, FAM138A, and RP11-175K6.1 in BLCA (Figure 5(a)), AC084018.1, HERC2P2, GOLGA2B, SH3BP5-AS1, CROCCP2, RP11-493K19.3, SEPT7P2, ZNF37BP, and RP11-228B15.4 in KIRC (Figure 5(b)), RP11-510M2.2, ZNF252P-AS1, UBE2Q2P2, ADORA2A-AS1, RP11-279F6.1, and MRPL23-AS1 in KIRP (Figure 5(c)), and RP1-163G9.1, LINC00675, AC003090.1, LINC00473, CYP4F8, AC017048.3, and ADAMTS9-AS1 in PRAD (Figure 4) were identified as key lncRNAs in cancer-specific lncRNAs coexpressing networks in urologic cancers.